CUBIST PHARMACEUTICALS, INC.Purchase Agreement • September 5th, 2013 • Cubist Pharmaceuticals Inc • Pharmaceutical preparations • New York
Cubist Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein (this “Agreement”), to issue and sell to the Initial Purchasers named in Schedule I hereto (the “Initial Purchasers”) an aggregate of $300,000,000 principal amount of the 1.125% Convertible Senior Notes due 2018 (the “2018 Firm Securities”) and an aggregate of $400,000,000 principal amount of the 1.875% Convertible Senior Notes due 2020 (the “2020 Firm Securities” and, together with the 2018 Firm Securities, the “Firm Securities”), and, at the election of the Initial Purchasers, to issue and sell up to an aggregate of $50,000,000 additional principal amount of the 1.125% Convertible Senior Notes due 2018 (the “2018 Optional Securities”) and an aggregate of $50,000,000 additional principal amount of the 1.875% Convertible Senior Notes due 2020 (the “2020 Optional Securities” and, together with the 2018 Optional Securities, the “Optional Securities”) (the Firm
